Aakko, S., Ylitalo, A., Kuusanmäki, H., Rannikko, J. H., Björkman, M., Mandelin, J., Heckman, C. A., Kontro, M., Hollmén, M. (2025). CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies. Scientific Reports. https://doi.org/10.1038/s41598-025-01675-y